Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01237457 · ClinicalTrials.gov registry record · Phase 2
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
A Phase 2 study, sponsored by Ebrahim S Delpassand.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT01237457 is a Phase 2 study that has completed, run by Ebrahim S Delpassand. The registered enrollment target is 143 participants.
The verdict
NCT01237457, a Phase 2 study, has completed, sponsored by Ebrahim S Delpassand.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This is a phase II treatment protocol evaluating 177Lu-DOTATATE therapy for somatostatin receptor-expressing cancers including, but not limited to, those arising from the neural crest and involving such organs as the lungs, breast, gastrointestinal tract, skin, and endocrine (examples: pheochromocytoma, medullary carcinoma of the thyroid, non-radioiodine avid differentiated thyroid cancer, melanoma, renal cell, Merkel cell, paraganglioma, small cell lung, Carcinoid, and pancreatic islet cell malignancies).
Interventions
- DRUG 177Lu-DOTATATE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2010-10-27 |
| Est. Completion | 2017-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01237457
The ClinicalTrials.gov registry entry for NCT01237457 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ebrahim S Delpassand, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 177Lu-DOTATATE is the first listed.
NCT01237457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01237457 about?
NCT01237457 is a clinical study titled "177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms". This is a phase II treatment protocol evaluating 177Lu-DOTATATE therapy for somatostatin receptor-expressing cancers including, but not limited to, those arising from the neural crest and involving such organs as the lungs, breast, gastrointestinal tract, skin, and endocrine (examples: pheochromocyt...
What is the current status of trial NCT01237457?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2010-10-27. Estimated completion is 2017-07-25.
What interventions are being tested in trial NCT01237457?
The interventions under investigation include: 177Lu-DOTATATE (DRUG).
Who is sponsoring clinical trial NCT01237457?
This trial is sponsored by Ebrahim S Delpassand, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.